Evidence map›Paper›PMID 39477439›Full record

ArticleIn vivo (Athens, Greece)

Genetic Variations in

Klaudia Hives Holeckova, Mark Hives, Marian Grendar, Henrieta Blahusiak Drobkova, Jan Kliment

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Klaudia Hives HoleckovaDepartment of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia.
Mark HivesDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Marian GrendarBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Henrieta Blahusiak DrobkovaBiomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
Jan KlimentDepartment of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia; jan.kliment@uniba.sk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis report aimed to present identified variants with pathogenic potential in three genes - TP53, PTEN, and RB1 - in a selected sample of patients with metastatic castration-resistant prostate cancer (mCRPC) with or without the presence of circulating tumor cells (CTCs) and splice variant AR-V7. MATERIALS AND

methodsNext generation sequencing was performed on an Illumina platform to analyse the genetic profiles of 50 patients with mCRPC. Identified variants were validated using the Integrative Genomic Viewer, and the correlation between these variants and the presence of CTC/AR-V7 was subjected to statistical analysis.

resultsThe study revealed a total of 15 genetic alterations in the three examined genes. The presence of rs1042522 (TP53) in mCRPC patients was associated with a significantly reduced likelihood of AR-V7 occurrence (p<0.001), indicating a protective effect. Additionally, patients with AR-V7 showed a marked increase in prostate-specific antigen (PSA) levels. Higher PSA levels were correlated with an increased risk of AR-V7 presence.

conclusionThe identified genetic mutations and PSA levels have a moderate predictive ability for determining AR-V7 status.

Indexed as

Prostatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseRetinoblastoma Binding ProteinsTumor Suppressor Protein p53Ubiquitin-Protein LigasesAgedAged, 80 and overBiomarkers, TumorGenetic VariationHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNeoplasm MetastasisNeoplastic Cells, CirculatingBiomarkers, TumorProstate-Specific AntigenPTEN PhosphohydrolasePTEN protein, humanRB1 protein, humanReceptors, AndrogenRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesARV-7CTCNGSProstate cancertumour-suppressor genes

Identifiers

PMID39477439
PMCPMC11535959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.